Chronic myelogenous leukemia: molecular monitoring in clinical practice
<p>Use of tyrosine kinase inhibitor imatinib has led to significant progress in chronic myeloid leukemia (CML) treatment. To date, genetic monitoring is a mandatory attribute of therapy with tyrosine kinase inhibitors. The purpose of this study was to access the imatinib therapy efficacy in CM...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2014-07-01
|
| Series: | Онкогематология |
| Subjects: | |
| Online Access: | http://oncohematology.abvpress.ru/index.php/ongm/article/view/39 |